112701-03-8

Basic information

• Product Name: 3H-Pyrazol-3-one, 1,2-dihydro-5-methyl-4-(phenylmethyl)-
• CAS NO: 112701-03-8
• Molecular Formula: C11H12N2O
• Molecular Weight: 188.229
• Mol File: 112701-03-8.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: 3H-Pyrazol-3-one, 1,2-dihydro-5-methyl-4-(phenylmethyl)-(CAS DataBase Reference)
• NIST Chemistry Reference: 3H-Pyrazol-3-one, 1,2-dihydro-5-methyl-4-(phenylmethyl)-(112701-03-8)
• EPA Substance Registry System: 3H-Pyrazol-3-one, 1,2-dihydro-5-methyl-4-(phenylmethyl)-(112701-03-8)

Safety Data

• Hazardous Substances Data: 112701-03-8(Hazardous Substances Data)

Upstream product

• 620-79-1 Ethyl 2-benzylacetoacetate 
• 100-44-7 benzyl chloride 
• 100-39-0 benzyl bromide 
• 68761-49-9 5-Methyl-4-[1-phenyl-meth-(Z)-ylidene]-2,4-dihydro-pyrazol-3-one 
• 3666-82-8 2-benzyl-3-oxo-butyric acid methyl ester 
• 153458-31-2 4-benzyl-3-methylisoxazol-5-amine 

Downstream Products

• 112701-04-9 2-Benzyl-2,3-butadiensaeure-methylester 

Relevant articles and documents

Discovery of remogliflozin etabonate: A potent and highly selective SGLT2 inhibitor

We optimized the structure of an active metabolite (1) of WAY-123783, which was obtained from mouse urine after oral administration, to improve selectivity for SGLT2 and oral bioavailability. O-glucoside derivative 24 (remogliflozin etabonate) was subsequently identified as a potent, highly selective, and orally available SGLT2 inhibitor.

Selective reduction exocyclic double bond of isoxazolones and pyrazolones by hantzsch 1,4-dihydropyridine

Hantzsch 1,4-dihydropyridine (HEH) was used to realize the selective reduction of the exocyclic double bond of 4-arylmethylene- and 4-alkylidene-4H-isoxazol-5-ones and 4-arylraethylene-4H-pyrazol-5-ones. Georg Thieme Verlag Stuttgart.

GLUCOPYRANOSYLOXYPYRAZOLE DERIVATIVES, MEDICINAL COMPOSITIONS CONTAINING THE SAME AND INTERMEDIATES IN THE PRODUCTION THEREOF

The present invention relates to glucopyranosyloxypyrazole derivatives represented by the general formula: wherein R1 represents a hydrogen atom or a lower alkyl group; one of Q1 and T1 represents a group represented by the general formula: while the other represents a lower alkyl group or a halo(lower alkyl) group; and R2 represents a hydrogen atom, a lower alkyl group, a lower alkoxy group, a lower alkylthio group, a halo(lower alkyl) group or a halogen atom, or pharmaceutically acceptable salts thereof, which have an inhibitory activity on human SGLT2 and are useful as agents for the prevention or treatment of diabetes, diabetic complications or obesity, and to pharmaceutical compositions comprising the same and intermediates thereof.